This is a prospective single center pilot randomized controlled study to assess the efficacy and safety of YiQiFuMai injection (YQFM), a widely used Chinese medicine, as an adjunctive treatment for sepsis.
No linked publications found in PubMed
Inclusion Criteria: * Sepsis defined by Sepsis-3 definition * Adult patients between the ages of 18 and 90. * Informed consent is provided by patients or obtained by family member if patient is incapacitated. Exclusion Criteria: * Known severe allergic reaction to drugs including but not limited to YQFM. * Pregnant patients or those who may be pregnant * Patients with severe intracranial diseases (intracranial artery stenosis, intracranial infection, cerebral hemorrhage, cerebral infarction, brain trauma, subjects after intracranial surgery) * Patients with extremely severe brain injury, after cardiopulmonary resuscitation, advanced malignant tumor, combined with serious primary diseases such as liver, lung, kidney and hematopoietic system, and poor prognosis; * Autoimmune diseases, immune deficiency diseases, continuous use of immunosuppressants within the last 6 months, or organ transplants; * Major surgery or trauma within the last 2 weeks; * Participated in other clinical trials or took similar drugs within 1 month; * The investigator considered that the subjects had poor compliance or other clinical, social, or family factors that were inappropriate for inclusion in the study.